We help companies reduce costs by releasing safe products to market faster
A rapid product release screening test from Celsis delivers definitive results 80% faster than traditional microbial methods, so Pharmaceutical, Home and Beauty and Food and Beverage companies can reduce hold times, reduce inventory requirements and reduce costs—without compromising quality.
As the world’s leading innovator in rapid detection, Celsis-designed systems are used globally by P&G, Unilever and many others to identify the absence or presence of contamination in as few as 18-24 hours. Our user-friendly instruments and proven assays generate results equivalent to traditional testing, only faster. Celsis has been accepted as the release method on new drug applications since 1997 and validated on many hundreds of different product types.
UK-based Celsis International Ltd. has offices in the United States, England, Germany and Belgium, with many hundreds of active systems in more than 65 countries, supported by a global network of experienced Celsis representatives and distribution partners. Someone is always available to help you succeed.
Celsis Facts
- Founded in 1992 in Cambridge, UK, by Sir Christopher Evans
- Privately held company
- CEO Jay LeCoque
Looking for more?
Celsis In Vitro Technologies is the premier supplier of high-quality hepatocytes, microsomes, s9, stellate and kupfner cells, cytosol and other custom cellular and sub-cellular products used to speed up ADME-Tox in vitro research for drug discovery and development. Celsis IVT, a division of Celsis International, holds a patent on the process of targeted, purpose-pooling of human hepatocytes for its unique LiverPool cryopreserved product. Other unique products include microsomes for targeted CYP activity levels and a robust custom products program that offers a wide range of product types by organ and by species. View product characterization tables or Contact Celsis IVT.
Celsis Analytical Services was recently purchased by AAIPharma Services Corp.
Back to Top
